Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Vir Biotechnology, Inc.
VIR
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.6B
$10.04
▲ +5.02%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$4.16 - $11.66
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 76.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary viral immunology platform enabling rapid therapeutic development
- Strategic partnerships with pharmaceutical giants (GSK, Alnylam, Gilead) providing distribution and credibility
- First-mover advantage with FDA-approved Xevudy generating commercial revenue
- Access to world-class manufacturing through Samsung Biologics partnership
- Funding validation from Bill & Melinda Gates Foundation and NIH demonstrating scientific merit
Bear Case
2 risks
- Above-average volatility (beta 1.6).
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Revenue decline expected
Expanding Xevudy market penetration globally for COVID-19 treatment and prevention
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Strong
+5.5% over 3m
Quality
Excellent
Emerging growth company (214% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying VIR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 6, 2026
Reported EPS of -$0.85 vs -$0.01 consensus (-8400.0% surprise). Revenue of $-29.0K vs $55.5M expected (-100.0%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-8400.0%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
-26%
-95%
-61%
-90%
+418%
-101%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$3.1M
$2.4M
$12.4M
$3.0M
$1.2M
$240.0K
$64.1M
-$29.0K
Margins · last 8Q
Operating
—
Profit
—
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$23.00
▲ +129.1% vs $10.04
Latest: Morgan Stanley · Jun 11, 2026
1 analyst covering